Prednisolone

First approved in 1955

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H28O5
Molecular Weight	360.444
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO

InChI

InChIKey=OIGNJSKKLXVSLS-VWUMJDOOSA-N

InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C21H28O5
Molecular Weight	360.444
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 7
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://books.google.ru/books?id=0vXTBwAAQBAJ&pg=PA1012&lpg=PA1012&dq=prednazate+prednisolone&source=bl&ots=6IVjr7YAxt&sig=n3FMmropI-ytuQms6m0VusBrXNc&hl=ru&sa=X&ved=0ahUKEwilpZPbib7PAhXMESwKHZaaB18Q6AEIOzAE#v=onepage&q=prednazate%20prednisolone&f=false Retrieved from Dictionary of drugs: Chemical data, structures and bibliographies, edited by J. Elks and C. R. Ganellin, p.1012http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdfhttps://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html | https://humanpara.org/prednisone-and-prednisolone/ | https://www.drugbank.ca/drugs/DB00860http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdfhttps://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3580023

Prednisolone hemisuccinate is a prodrug of a glucocorticoid agonist prednisolone, which is marketed under trade name Prednisolut in Germany and Austria. Prednisolone hemisuccinate is used in emergency medicine to treate shock due to allergic reaction, insect and snake bites, in neurology to treat brain edema and meningitis, in transplantation medicine to reduce risk of organ refection after kidney transplane, in pneumology to treat acute asthma attack, pulmonary edema, in severe or life-threatening situation in rheumatic diseases.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25965047 \| https://www.drugbank.ca/drugs/DB00860	Agonist 2752	5.7 nM [EC50]
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Agonist 2752
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://dictionary.sensagent.com/prednisone/en-en/	Agonist 2752
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: https://www.genome.jp/dbget-bin/www_bget?dr:D08413	Agonist 2752
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Agonist 2752	2.4 nM [Ki]
Glucocorticoid and meneralocorticoid receptor agonists/antagonists 23 Target ID: map07225 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D02156	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Allergic states 22 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Mycosis fungoides 31 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Primary or secondary adrenocortical insufficiency 22 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Hematologic disorders 22 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Acute leukemia 32 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Multiple sclerosis 107 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Uveitis 28 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Symptomatic sarcoidosis 22 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Rheumatic diseases 31 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Inflammation and pain 22 Sources: (2013) Arthritis: New Insights for the Healthcare Professional, page 345, retrieved from: https://books.google.ru/books?id=YvMIwDn3a20C	Palliative	Approved 8583	Sixtysix-20 Approved Use Antiinflammatory agent
Atopic dermatitis 64 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Severe erythema multiforme (Stevens-Johnson syndrome) 22 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Congenital adrenal hyperplasia 62 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Crohn's disease 64 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Diamond-Blackfan anemia 24 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Aggressive lymphoma 24 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Allergic conjunctivitis 101 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Acne rosacea 44 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Superficial punctate keratitis 43 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Herpes zoster keratitis 44 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Iritis 43 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Anaphylaxis 47 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Curative	Approved 8583	Prednisolut Approved Use Prednisolut is indicated in shock and emergency medicine: Shock due to a severe allergic reaction (anaphylactic shock), after previous treatment with epinephrine, progressive forms of allergic reactions in insect bites and snake bites
Brain edema 22 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Primary	Approved 8583	Prednisolut Approved Use Brain swelling (brain edema), triggered by brain tumor, neurosurgery, brain abscess, bacterial meningitis (meningitis).
Acute asthma attack 22 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Primary	Approved 8583	Prednisolut Approved Use Prednisolut is indicated to treat acute asthma attack, pulmonary edema by inhalation of toxic substances such as chlorga's, isocyanates, hydrogen sulphide, phosgene, nitrose gas, ozone, also nitrogen oxide, by gastric juice aspiration, and by drown.
Pulmonary edema 25 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Primary	Approved 8583	Prednisolut Approved Use Prednisolut is indicated to treat acute asthma attack, pulmonary edema by inhalation of toxic substances such as chlorga's, isocyanates, hydrogen sulphide, phosgene, nitrose gas, ozone, also nitrogen oxide, by gastric juice aspiration, and by drown.
Rheumatoid arthritis 320 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Primary	Approved 8583	Prednisolut Approved Use Prednisolut is indicated for treatment of severe / life-threatening situations in the following rheumatic diseases: rheumatoid arthritis and still syndrome, felty syndrome, polymyalgia rheumatica, systemic juvenile idiopathic arthritis (eg breast disease, seropositive polyarthritis), collagenoses, vasculitides, rheumatic fever.

C_max

Value	Dose	Analyte	Population
0.054 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513854/	60 mg single, enteral dose: 60 mg route of administration: Enteral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
33.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12616672/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
41.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
43.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
15.4 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17925494	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
420.91 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
14.43 ng/mL DRUG LABEL https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/672212_2456402C1044_3_03#page=4	40 mg single, intramuscular dose: 40 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	PREDNISOLONE blood	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
86 μg/dL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/343018_2456405D1027_2_016_1F.pdf#page=31	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
36 μg/dL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/343018_2456405D1027_2_016_1F.pdf#page=31	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	PREDNISOLONE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
0.484 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513854/	60 mg single, enteral dose: 60 mg route of administration: Enteral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
298 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12616672/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
358 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
387 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
97 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17925494	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2408.1 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
0.025 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.0173 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.085 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.0601 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
5.11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513854/	60 mg single, enteral dose: 60 mg route of administration: Enteral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.85 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17925494	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.6 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
4 h OTHER https://www.pdr.net/drug-summary/Omnipred-prednisolone-acetate-1102.1749#15		PREDNISOLONE plasma	Homo sapiens
30 min OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/343018_2456405D1027_2_016_1F.pdf#page=31	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
25 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
18 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
50% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2199128		PREDNISONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
20% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
10% OTHER https://www.pdr.net/drug-summary/Omnipred-prednisolone-acetate-1102.1749#15		PREDNISOLONE plasma	Homo sapiens
23% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://doi.org/10.1016/B978-0-12-385157-4.00633-3 https://pubmed.ncbi.nlm.nih.gov/33663183	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://doi.org/10.1016/B978-0-12-385157-4.00633-3 https://pubmed.ncbi.nlm.nih.gov/33663183	Sources: https://doi.org/10.1016/B978-0-12-385157-4.00633-3 https://pubmed.ncbi.nlm.nih.gov/33663183
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	Disc. AE: Vertigo, Abdominal pain upper... AEs leading to discontinuation/dose reduction: Vertigo (1%) Abdominal pain upper (1%) Gastroesophageal reflux disease (1%) Intestinal functional disorder (1%) Nausea (1%) Dizziness (1%) Aphasia (1%) Headache (1%) Renal pain (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
1 % 4 times / day multiple, ophthalmic Recommended Dose: 1 %, 4 times / day Route: ophthalmic Route: multiple Dose: 1 %, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762913/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17762913/	Sources: https://pubmed.ncbi.nlm.nih.gov/17762913/

AEs

AE	Significance	Dose	Population
Abdominal pain upper	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Aphasia	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Dizziness	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Gastroesophageal reflux disease	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Headache	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Intestinal functional disorder	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Nausea	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Renal pain	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Vertigo	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	11-beta-HSD2 48 11-beta-HSD1 33 P-gp 2052	P-gp 301 BCRP 101 MRP1 74 MRP4 53 MRP5 45 ABCC12 43 MRP2 146 MRP3 83

Drug as perpetrator

Target	Modality	Activity
ABCC12 43	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
BCRP 985	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP1 232	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP3 326	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/15979871/ Page: -	no
MRP4 345	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP5 80	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
P-gp 1932	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP2 625	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/15979871/ Page: -	yes

Drug as victim

Target	Modality	Activity
11-beta-HSD2 48	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349812/ Page: -	major
11-beta-HSD1 33	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349812/ Page: -	minor
P-gp 2052	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349812/ Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8382	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8382
ChemicalBook	CB44844383	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB44844383
ChemicalBook	CB6716222	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6716222
eMolecules	29549912	https://www.emolecules.com/cgi-bin/more?vid=29549912
eMolecules	29703823	https://www.emolecules.com/cgi-bin/more?vid=29703823
eMolecules	31411020	https://www.emolecules.com/cgi-bin/more?vid=31411020
eMolecules	494851	https://www.emolecules.com/cgi-bin/more?vid=494851
MolPort	MolPort-001-740-041	https://www.molport.com/shop/molecule-link/MolPort-001-740-041
Selleck Chemicals	Prednisone	http://www.selleckchem.com/products/Prednisone.html
ZINC	ZINC000003875357	http://zinc15.docking.org/substances/ZINC000003875357
ChEBI	CHEBI:8378	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8378
ChemicalBook	CB4109000	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4109000
eMolecules	30512726	https://www.emolecules.com/cgi-bin/more?vid=30512726
eMolecules	31411129	https://www.emolecules.com/cgi-bin/more?vid=31411129
eMolecules	36644749	https://www.emolecules.com/cgi-bin/more?vid=36644749
eMolecules	511677	https://www.emolecules.com/cgi-bin/more?vid=511677
MolPort	MolPort-002-507-147	https://www.molport.com/shop/molecule-link/MolPort-002-507-147
Selleck Chemicals	Prednisolone(Hydroretrocortine)	http://www.selleckchem.com/products/Prednisolone(Hydroretrocortine).html
ZINC	ZINC000003833821	http://zinc15.docking.org/substances/ZINC000003833821

PubMed

Title	Date	PubMed
Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis.	2008-02-01	17988236
[Acceptability and tolerance of prednisolone metasulfobenzoate in orally dispersing tablets in 2 to 12-years-old children].	2004-09	15351007
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.	2001-03-01	11222362
Sample size calculations for the two-sample problem using the multiplicative intensity model.	2001-02-28	11223901
Retinopathy due to juvenile polymyositis.	2001-02-24	11201918
Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia.	2001-02-15	11181667
Fistulation of the auditory tube diverticulum (guttural pouch) with a neodymium:yttrium-aluminum-garnet laser for treatment of chronic empyema in two horses.	2001-02-01	11201568
Current status of cytotoxic chemotherapy in hormone refractory prostate cancer.	2001-02	11223670
Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease.	2001-02	11216711
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.	2001-02	11216706
Hepatic dysfunction as the presenting feature of acute lymphoblastic leukemia.	2001-02	11216703
Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon.	2001-02	11211616
The usefulness of quantitative orbital magnetic resonance imaging in Graves' ophthalmopathy.	2001-02	11207635
Mycophenolic acid plasma concentrations: influence of comedication.	2001-02	11206040
Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine.	2001-02	11205659
Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: results of a randomized controlled trial.	2001-02	11205648
Recalcitrant allergic contact dermatitis from azathioprine tablets.	2001-02	11205401
Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.	2001-02	11182026
[Can 67Ga citrate predict the efficacy of chemotherapy early in Hodgkin's lymphoma?].	2001-02	11181330
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].	2001-02	11181327
Can we induce tolerance in rheumatoid arthritis?	2001-02	11177772
Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection.	2001-01-27	11213064
Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.	2001-01-16	11177313
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.	2001-01-16	11177311
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.	2001-01-15	11208830
[Life threatening hypercalcemia in a young man with ALL].	2001-01-05	11200666
Autologous hematopoietic stem-cell transplantation for Behçet's disease with pulmonary involvement.	2001-01-04	11187123
Remission of precapillary pulmonary hypertension in systemic lupus erythematosus.	2001-01	11220068
Pyodera gangrenosum after aortic valve replacement.	2001-01	11216779
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.	2001-01	11212161
Gingival overgrowth as the initial paraneoplastic manifestation of Hodgkin's lymphoma in a child. A case report.	2001-01	11210066
Lupus-like syndrome with submassive hepatic necrosis associated with hepatitis A.	2001-01	11206308
Macrohematuria with electron-dense deposits in a 14-year-old boy with minimal change nephrotic syndrome.	2001-01	11198614
Fatal cytomegalovirus disease in a high-risk renal transplant recipient.	2001-01	11198610
Nocardia pleural empyema complicating anti-Jo1 positive polymyositis during immunoglobulin and steroid therapy.	2001-01	11196531
Systemic vasculitis in patients with hepatitis C.	2001-01	11196510
Factors associated with low bone mineral density in female patients with systemic lupus erythematosus.	2001-01	11196509
A rationale for adjuvant surgical intervention in pyoderma gangrenosum.	2001-01	11192029
Effective steroid-sparing treatment for peripheral ulcerative keratitis and pyoderma gangrenosum.	2001-01	11188994
Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome.	2001-01	11182286
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.	2001-01	11180038
Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome.	2001	11223743
Bilateral empyema caused by adult-onset Still's disease.	2001	11223737
Choroidal granulomas in systemic sarcoidosis.	2001	11217928
Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers.	2001	11215697
Hodgkin's disease: clinical presentation and treatment.	2001	11191130
Validation of liquid-liquid extraction followed by flow-injection negative ion electrospray mass spectrometry assay to Topiramate in human plasma.	2001	11180545
The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents.	2001	11178116
Prednisone is more effective than prednisolone metasulfobenzoate in the treatment of bullous pemphigoid.	1999-01	9923789
Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone.	1993	8513854

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:51:25 GMT 2025` Edited by `admin` on `Mon Mar 31 17:51:25 GMT 2025`
Record UNII	9PHQ9Y1OLM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE

Preferred Name

English

Prednisolone

Official Name

English

METI-DERM

Brand Name

English

NSC-9120

Code

English

METHYLPREDNISOLONE IMPURITY K [EP IMPURITY]

Common Name

English

NSC-9900

Code

English

11.BETA.,17,21-TRIHYDROXYPREGNA-1,4-DIENE-3,20-DIONE.

Common Name

English

11?,17,21-Trihydroxypregna-1,4-diene-3,20-dione

Systematic Name

English

PREDNISOLONE (EMA EPAR: VETERINARY)

Common Name

English

PREDNISOLONE [MART.]

Common Name

English

(+)-PREDNISOLONE

Common Name

English

PREDNISOLONE [ORANGE BOOK]

Common Name

English

PREDNISONE IMPURITY B [EP]

Common Name

English

PREDNISOLONE ANHYDROUS

Common Name

English

DELTAHYDROCORTISONE

Common Name

English

APREDNISLON

Common Name

English

PREDNISOLONE [EP]

Common Name

English

PREDNICARBATE IMPURITY A [EP IMPURITY]

Common Name

English

Prednisolone [WHO-DD]

Common Name

English

DELTA-CORTEF

Brand Name

English

PREDNISOLONE [JAN]

Common Name

English

EQUISOLON

Brand Name

English

PREDNISOLONE [HSDB]

Common Name

English

PREDNISOLONE ACETATE IMPURITY B [EP IMPURITY]

Common Name

English

PANAFCORTELONE

Common Name

English

HYDRORETROCORTINE

Common Name

English

PREDNISOLONUM [WHO-IP LATIN]

Common Name

English

prednisolone [INN]

Common Name

English

CODELCORTONE

Common Name

English

FERNISOLONE-P

Brand Name

English

PREDNISOLONE [MI]

Common Name

English

PREDNISOLONE [EP MONOGRAPH]

Common Name

English

PREDNISOLONE [VANDF]

Common Name

English

PREDNISOLONE [USP-RS]

Common Name

English

PREDNISOLONE [GREEN BOOK]

Common Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 11,17,21-TRIHYDROXY-, (11.BETA)-

Common Name

English

SUPERCORTISOL

Common Name

English

DELTACORTRIL

Brand Name

English

PREDNISOLONE [WHO-IP]

Common Name

English

PREDNISOLONE [USP MONOGRAPH]

Common Name

English

METACORTANDRALONE

Common Name

English

STERANE

Brand Name

English

VETSOLONE

Common Name

English

CORTALONE

Brand Name

English

HYDROCORTISONE IMPURITY A [EP IMPURITY]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QS03CA02